



Afimmune  
Trintech Building  
South County Business Park  
Leopardstown, Dublin 18  
t +353 (1) 294 6380  
[info@afimmune.com](mailto:info@afimmune.com)  
[www.afimmune.com](http://www.afimmune.com)

**EudraCT Number:** 2020-002911-23

**Study ID:** DS102A-08-CV2

**Study Title:** A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study to Assess the Mechanism of Action and Safety of Orally Administered Epeleuton in Patients with Type 2 Diabetes and Diabetic Complications.

**Date of early termination:** 08 April 2022

**Reason why study was early terminated:** The early termination reflects a business decision by Afimmune Ltd. to stop the study and is not due to a safety concern. Seven patients have been screened, no patient has been randomised into the trial.

Consequently, no results are available for this trial.